Ligand Pharmaceuticals, a biotechnology company, has reported that its partner, Pfizer has received approval from the European Commission for Fablyn tablets, a selective estrogen receptor modulator for the
HemCon Medical Technologies, a developer of advanced medical products, has announced improved results from an independent study investigating the time required to successfully treat fungal infected human nails
Vertex Pharmaceuticals, a biotechnology company, has initiated a Phase IIa clinical trial for VX-809, an investigational cystic fibrosis transmembrane conductance regulator corrector that targets the defective CFTR protein
Antares Pharma, a pharma product development company, has reported a net loss of $2.74m, or $0.04 per share, for the fourth quarter of 2008, compared to a net
Neurocrine Biosciences, a product based biopharmaceutical company, has announced top-line efficacy and safety results from its fourth Phase II clinical trial using its orally-active nonpeptide gonadotropin-releasing hormone receptor
Financial highlights Adjusted EBITDA(2) 2008: GBP12.3 million (Pro forma(1) 2007: GBP8 million) – 54% increase Operating Profit of GBP4.2 million (2007: GBP2 million) – 114% increase Adjusted basic
ReGen Therapeutics, a company engaged in the drug development and ancillary services, has signed an agreement with Golgi Pharmaceuticals, a distributor of pharmaceuticals and nutraceuticals, to extend the
Radius Health, a developer of new drug therapies for osteoporosis and women’s health, has dosed the first patient in the company’s proof-of-concept Phase IIa study of RAD1901, an
Corporate Update “We accomplished many significant Company goals during 2008 and especially in the fourth quarter, despite the current market conditions which have negatively impacted our share price,”
According to Regenerx, RGN-137 is a topical gel formulation of thymosin beta 4 peptide. The drug candidate was found to be safe and well-tolerated at all three dose
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.